NEW YORK, NY--(Marketwired - Feb 25, 2016) - Kadmon Corporation, LLC today announced preclinical data demonstrating that selective inhibition of rho-associated coiled-coil kinase 2 (ROCK2), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback